Abstract
Three quite different forms of direct antiarrhythmic therapy are available for the treatment of cardiac arrhythmias: antiarrhythmic drugs, cardiac ablation and implantable devices (pacemakers and defibrillators). None of these therapies is fully effective and consequently they are increasingly combined. This combination therapy is often described as “hybrid” a term that implies fundamental different qualities of treatment which together provide some form of synergism. The mechanisms for the initiation and perpetuation of most cardiac arrhythmias are complex and multiple. It is therefore not surprising that single therapies are not completely effective. Theoretically the use of multiple different therapies allows more specific mechanisms of arrhythmia to be directly addressed. However, this is largely a theoretical concept that has only been strictly evaluated in a small number of studies. Studies of multiple therapies are difficult to perform unless the combination therapy is regarded as a strategy which can be compared to baseline, conventional treatment or one or more single constituent therapies from the combination. Despite the lack of formal studies there is a very substantial clinical experience which testifies to the value of hybrid therapy for the management of both atrial fibrillation and ventricular tachycardia/fibrillation.
Similar content being viewed by others
References
Krol RB, Saksena S, Prakash A. New devices and hybrid therapies for treatment of atrial fibrillation. J Interv Card Electrophysiol 2000;4:163–169.
Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998;82:2N–9N.
Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995;92:1954–1968.
Singh BN, Sarma JS. Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias. J Cardiovasc Pharmacol Ther 2001;6:69–87.
Steinbeck G. Evolution of implantable cardioverter de-fibrillator indications: Comparison of guidelines in the United States and Europe. J Cardiovasc Electrophysiol 2002;13:S96–S99.
Israel CW, Gronefeld G, Ehrlich JR, Hohnloser SH. Suppression of atrial tachyarrhythmias by pacing. J Cardiovasc Electrophysiol 2002;13:S31–S39.
Prakash A, Saksena S, Krol RB, et al. Catheter ablation and antiarrhythmic drugs (“hybrid therapy”) improves rhythm control in patients with refractory atrial fibrillation. J Interv Card Electrophysiol 2002;6:165–172.
Rajawat YS, Dias D, Gerstenfeld EP, et al. Interactions of antiarrhythmic drugs and implantable devices in controlling ventricular tachycardia and fibrillation. Curr Cardiol Rep 2002;4:434–440.
Qi X, Dorian P. Antiarrhythmic drugs and ventricular defibrillation energy requirements. Chin Med J (Engl) 1999;12:1147–1152.
Defaye P, Mouton E. A new diagnostic concept in cardiac pacing for the evaluation of the incidence of atrial arrhythmias. Results of the AIDA study. Arch Mal Coeur Vaiss 1999;92:719–726.
Somberg JC. Proarrhythmia or arrhythmogenicity. Am J Ther 1995;2:449.
Ricci R, Pignalberi C, Disertori M, et al. Efficacy of a dual chamber defibrillator with atrial antitachycardia functions in treating spontaneous atrial tachyarrhythmias in patients with life-threatening ventricular tachyarrhythmias. Eur Heart J 2002;23:1471–1479.
Daubert C, Gras D, Berder V, et al. Permanent atrial resynchronization by synchronous bi-atrial pacing in the preventive treatment of atrial flutter associated with high degree interatrial block. Arch Mal Coeur Vaiss 1994;87:1535–1546.
Israel CW, Ehrlich JR, Barold SS, Hohnloser SH. Treatment of atrial tachyarrhythmias with pacing and antiarrhythmic drugs. In: Israel CW, Barold SS, eds. Advances in the Treatment of Atrial Tachyarrhythmias: Pacing, Cardioversion, and Defibrillation. Armonk, NY: Futura Publishing Co., Inc., 2002:305–323.
Keren G, Miura DS, Somberg JC. Pacing termination of ventricular tachycardia: Influence of antiarrhythmicslowed ectopic rate. Am Heart J 1984;107:638–643.
Naccarelli GV, Zipes DP, Rahilly T, et al. Influence of tachycardia cycle length and antiarrhythmic drugs on pacing termination and acceleration of ventricular tachycardia. Am Heart J 1983;105:1–5.
Newman D, Dorian P, Hardy J. Randomized controlled comparison of antitachycardia pacing algorithms for termination of ventricular tachycardia. J Am Coll Cardiol 1993;21;1413–1418.
Gottlieb CD, Horowitz LN. Potential interactions between antiarrhythmic medication and the automatic implantable cardioverter defibrillator. PACE 1991;14:898–904.
Steinberg JS, Martins J Sadanandan S, et al and the AVID Investigators. Antiarrhythmic drug use in the implantable defibrillator arm of the antiarrhythmics versus implantable defibrillators (AVID) study. An Heart J 2001;142:520–529.
Pacifico A, Hohnloser SH, Williams JH, et al. For the d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med 1999;340:1855–1862.
Anderson JL, Karagounis LA, Roskelley M, et al. Effect of prophylactic antiarrhythmic therapy on time to implantable cardioverter-defibrillator discharge in patients with ventricular tachyarrhythmias. Am J Cardiol 1994;73:683–687.
Lau CP, Tse HF, Yu CM, et al. for the New Indication for Preventive Pacing in Atrial Fibrillation (NIPPAF) Investigators. Dual-site atrial pacing for atrial fibrillation in patients without bradycardia. Am J Cardiol 2001;88(4):371–375.
Ricci R, Santini M, Puglisi A, et al. Impact of consistent atrial pacing algorithm on premature atrial complexes number and paroxysmal atrial fibrillation recurrences in brady-tachy syndrome: A randomized prospective cross over study. J Interv Card Electrophysiol 2001;5:33–44.
Attuel P, Konz KH, Brachmann J, et al. for the InosDDD+ Study Investigators. Prevention of atrial fibrillation by DDD+ atrial overdrive pacing: Final results of a randomised crossover study (Abstract). Eur Heart J 2002;23:139.
Barnay C, De Roy L, Seidl K, et al. Impact of antiarrhythmic therapy on the efficacy of AF prevention pacing (Abstract). Europace 2002;3:A230.
Israel CW, Grönefeld G, Hügl B, et al. Amiodarone increases the utility of atrial antitachycardia pacing (Abstract). Europace 2002;3:A249.
Konz KH, Szendey I, El Allaf D, et al. Influence of concomitant drug therapy on the efficacy of atrial overdrive stimulation (Abstract). Europace 2002;3:A249.
Saksena S, Prakash A, Ziegler, et al. for the DAPPAF Investigators. Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy. J Am Coll Cardiol 2002;40:1140–1150.
Sorrentino RA, Shenasa M, Deering T, et al. Antiarrhythmic effect on quality of life for patients in the PAC-ATACH trial (Abstract). Circulation 1999;100:I-452–I-453.
Santini M, Pandozi C, Ricci R. Combining antiarrhythmic drugs and implantable devices therapy: Benefits and outcome. J Interv Card Electrophysiol 2000;4(Suppl 1):65–68. Review.
Essebag V, Hadjis T, Platt RW, Pilote L. Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. J Am Coll Cardiol 2003;41:249–254.
Krol RB, Saksena S, Prakash A. Interactions of antiarrhythmic drugs with implantable defibrillator therapy for atrial and ventricular tachyarrhythmias. Curr Cardiol Rep 1999;1:282–288.
Greene HL. Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy. Am J Cardiol 1996;78:61A–66A.
Movzowitz C, Marchlinski FE. Interactions between implantable cardioverter-defibrillators and Class III agents. Am J Cardiol 1998;82:41I–48I.
Qi XQ, Newman D, Dorian P. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. J Interv Card Electrophysiol 1999;3:61–67.
Higgins SL, Yong P, Scheck D, et al. for the Ventak CHF Investigators. Biventricular pacing diminishes the need for implantable cardioverter defibrillator therapy. J Am Coll Cardiol 2000;36:824–827.
Walker S, Levy TM, Rex S, et al. Usefulness of suppression of ventricular arrhythmia by biventricular pacing in severe congestive heart failure. Am J Cardiol 2000;86:231–233.
Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. J Card Fail 2000;6:276–285.
Salukhe TV, Francis DP, Sutton R. Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) trial terminated early; combined biventricular pacemaker-defibrillators reduce all-cause mortality and hospitalization. Int J Cardiol 2003;87:119–120.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Camm, A.J., Savelieva, I. Rationale and Patient Selection for “Hybrid” Drug and Device Therapy in Atrial and Ventricular Arrhythmias. J Interv Card Electrophysiol 9, 207–214 (2003). https://doi.org/10.1023/A:1026288508343
Issue Date:
DOI: https://doi.org/10.1023/A:1026288508343